Human Immunodeficiency Virus Pre-exposure Prophylaxis Program in General Practice

NCT06258876 | Not Yet Recruiting

• 1 other identifier: APHP220156
• Study Type: observational
• Target: 400
• Locations: 0 countries
• Sites: N/A

Brief Summary

The Human Immunodeficiency Virus (HIV) epidemic persists in France, with approximately 6000 new cases per year. Various prevention tools against HIV exist, including condoms, regular testing, Post-Exposure Prophylaxis (PEP), HIV treatment for seropositive partners, single-use disposable injection equipment for drug use and pre-exposure prophylaxis (PrEP). Continuous or on-demand PrEP with tenofovir disoproxil fumarate/emtricitabine has proven effective in reducing the risk of HIV infection. France was the first European country to authorize PrEP, leading to an unprecedented impact on seropositivity discovery rates in 2018, with a 7% decrease in new infections compared to 2017. However, the effectiveness of PrEP can be hindered by challenges in retaining users within the healthcare system. According to the EPIPHARE report, which has been monitoring Truvada® or generic PrEP use since 2017, a substantial proportion of new users do not receive PrEP renewal in the first 6 months after initiation. Such early interruptions, increasing in frequency, affected around a quarter of individuals who initiated PrEP in the second half of 2021. A recent study reported that these early interruptions have a significant detrimental impact on PrEP effectiveness in real life, especially among those under 30 years old and in socio-economic precarious situations. The main barriers to PrEP adherence are multifactorial, including social precarity, limited PrEP access, and a low perception of HIV risk. To address this, in France, general practitioners have been authorized to issue initial PrEP prescriptions since June 1, 2021. The future challenge is to increase PrEP use and optimize retention to combat the HIV epidemic, relying significantly on general medicine. The goal of our study is to broaden PrEP access by optimizing its initial prescription in general medicine and to assess user retention in PrEP care through the established partnership between general practitioners and patients. The research will be conducted in collaboration between Saint Louis Hospital in the 10th arrondissement of Paris and general practitioners willing to participate in the study, located in the 3rd, 10th, 11th, 13th, and 19th arrondissements. Participating general practitioners may be in private practice, employed in health centers, or working in health houses. As part of the study, general practitioners will receive training from the infectious diseases department of Saint-Louis and Lariboisière hospitals. This training will be both theoretical and practical, with the opportunity to attend initiation and follow-up PrEP consultations in the department. A dedicated phone line in the infectious diseases department of Saint Louis Hospital will be available for participating general practitioners seeking specialized advice. They will be encouraged to register as PrEP prescribers in their appointment scheduling software. Patients will be informed of the study objectives and its process by the general practitioner, and their oral non-opposition will be collected. Each inclusion consultation will last approximately 20-40 minutes, allowing the general practitioner to prescribe PrEP, conduct the usual care consultation, and collect clinical, demographic, socio-economic, lifestyle, medical history, and patient vaccination data on a dedicated data collection form. The follow-up duration will be two years, with consultation frequency matching that of regular PrEP follow-ups, and data collection will occur at M6, M12, M18, and M24 using a dedicated data collection form. Data collected during inclusion and follow-up consultations will be anonymized and integrated into the electronic Clinical Report Form. During each PrEP consultation (initiation and follow-up), general practitioners will provide patients with a PrEP prescription if the pre-PrEP biology report allows it (according to HAS (Haute Autorité de Santé) recommendations). For patients who have not been attending consultations, a telephone survey will be offered to inquire about PrEP continuation and collect information on follow-up or reasons for stopping PrEP.

Conditions

Human Immunodeficiency Virus

Keywords

Pre-exposure Prophylaxis

Outcome Measures

Primary Outcomes (1)

• Percentage of patients still on PrEP

  Any patient having a general medicine consultation with a PrEP prescription between 21 and 27 months following the first PrEP prescription

  At 2 years

Secondary Outcomes (14)

• Percentage of Patients still on PrEP

  At 6 months

• Percentage of Patients still on PrEP

  At 12 months

• Percentage of Patients still on PrEP

  At 18 months

• Characteristics of PrEP-Using Populations Initiated in General Medicine

  Up to 2 years

• Characteristics of HIV at-Risk Populations with Limited Access to PrEP

  At baseline

Study Arms (1)

Patients with an indication for PrEP

\- Any patient presenting to a general medicine consultation for initial PrEP prescription or having previously received a hospital-initiated PrEP prescription, in a CEGGID (Centres gratuits d'information, de dépistage et de diagnostic), in a sexual health center, and not having had a PrEP prescription renewal for at least 4 months. OR \- Any patient seen in a general medicine consultation with an indication for PrEP.

Other: PrEP in general practice

Interventions

PrEP in general practice OTHER

Prescription and follow-up of PrEP in general practice

Patients with an indication for PrEP

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Any patient presenting to a general medicine consultation for initial PrEP prescription or having received a hospital-initiated PrEP prescription, in a CEGGID, in a sexual health center, and not having had a PrEP prescription renewal for at least 4 months. Also, any patient seen in a general medicine consultation with an indication for PrEP.

You may qualify if:

• Age ≥ 18 years
• Informed and provided verbal non-opposition
• Patient not infected with HIV and confirmed negative for the detection of antibodies produced in response to the HIV virus within the last 7 days (Elisa test) or recognized as having a negative HIV viral load
• Patient presenting in a general medicine consultation for:
• Initial prescription of PrEP
• Renewal consultation for PrEP (previously provided in a hospital, CEGGID, or sexual health center) without a PrEP prescription renewal for at least 4 months
• Consultation for another reason in general medicine and the patient presents one or more indications for PrEP prophylaxis:
• Belonging to one of these risk groups :
• MSM (men who have sex with men)
• Transgender individuals having relationships with men
• Individuals from regions with a high HIV prevalence (sub-Saharan Africa, Caribbean, South America)
• Sex workers
• Injectable drug users
• Any individuals (men and women) whose sexual partners belong to these populations
• b) Individual situation of high HIV exposure:

You may not qualify if:

• Patient with a contraindication to PrEP:
• Renal insufficiency with creatinine clearance \< 60 ml/min
• Hypersensitivity to the components of PrEP (tenofovir disoproxil, emtricitabine, or excipients of the product)
• Patient refusal to participate in the study
• Patient who received a renewal of the PrEP prescription less than 4 months ago
• Patient under guardianship, curatorship, or legal protection

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

HIV Infections; Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Central Study Contacts

Victoria Manda, Dr

CONTACT

+331 42 49 45 12; victoria.manda@aphp.fr

Jérôme Lambert, Pr

CONTACT

+33142499742; jerome.lambert@u-paris.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 23, 2024
• First Posted: February 14, 2024
• Study Start: February 15, 2024
• Primary Completion (Estimated): February 15, 2027
• Study Completion (Estimated): February 15, 2027
• Last Updated: February 14, 2024

Record last verified: 2024-01